Delcath Systems, Inc.

NASDAQ:DCTH

9.54 (USD) • At close September 13, 2024
Bedrijfsnaam Delcath Systems, Inc.
Symbool DCTH
Munteenheid USD
Prijs 9.54
Beurswaarde 267,115,230
Dividendpercentage 0%
52-weken bereik 2.25 - 11.745
Industrie Medical Devices
Sector Healthcare
CEO Mr. Gerard J. Michel MBA, MS
Website https://www.delcath.com

An error occurred while fetching data.

Over Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and

Vergelijkbare Aandelen

Check-Cap Ltd. logo

Check-Cap Ltd.

CHEK

1.79 USD

Cabaletta Bio, Inc. logo

Cabaletta Bio, Inc.

CABA

4.11 USD

Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp.

TNXP

0.157 USD

Immunome, Inc. logo

Immunome, Inc.

IMNM

15.97 USD

Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc.

TARA

1.88 USD

X4 Pharmaceuticals, Inc. logo

X4 Pharmaceuticals, Inc.

XFOR

0.71 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)